The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Treatment of Helicobacter pylori Infection: A Review of the World Literature
Abstract
Background.None of the currently used anti‐Helicobacter pylori drug regimens cures the infection 100%, and cure results still vary considerably. The present article reviews the effectiveness of currently used antimicrobial regimens, aimed to cure H. pylori infection. Methods.Data collection started from the beginning of the anti‐H. pylori‐therapy era until May 1995. No attempt at formal metanalysis has been made, because many studies have been published only in abstract form. Attempts were made to exclude duplicates of studies by comparison to previously reported ones; the authors of suspected duplicates were contacted. After amalgamation of the number of included patients and the number of successfully treated patients, the mean values of eradication rates and the 95% confidence intervals were calculated. Results.A total of 237 treatment arms were analyzed. Bismuth triple therapy continues to reach high eradication rates worldwide (78–89%). Side effects leading to diminished patient compliance and the marked decline of eradication efficacy in cases of metronidazole resistance are considered to be the major drawbacks of this therapy. Proton pump inhibitor (PPI) dual therapy is better tolerated with fewer side effects than is bismuth triple therapy. The mean eradication rates vary from 55 to 75%, and the extremes lie between 24 and 93%. PPI triple therapies have been shown to be very effective against H. pylori (eradication rates, 80–89%). Quadruple therapy leads to a mean eradication rate of 96%. Conclusion.Based on efficacy, PPI triple or bismuth triple therapy are recommended as first‐line treatment for H. pylori infection. Quadruple therapy could serve as second‐line treatment for eradication of initial failures and in case of metronidazole resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helicobacter pylori in Peptic Ulcer Disease
Yamada, T. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520010077036 · Cited by 1,024
Cure of duodenal ulcer associated with eradication of Helicobacter pylori
Rauws, E. A. J., & Tytgat, G. N. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91301-p · Cited by 922
Self-citationGraham, D. Y., Lew, G. M., Klein, P. D., Evans, D. G., Evans, D. J., Saeed, Z. A., & Malaty, H. M. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-9-705 · Cited by 909
Hentschel, E., Brandstatter, G., Dragosics, B., Hirschl, A. M., Nemec, H., Schutze, K., Taufer, M., & Wurzer, H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302043280503 · Cited by 708
Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action
Edwards, D. I. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.1.9 · Cited by 606
Factors influencing the eradication of Helicobacter pylori with triple therapy
Graham, D. Y., Lew, G. M., Malaty, H. M., Evans, D. G., Evans, D. J., Klein, P. D., Alpert, L. C., & Genta, R. M. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90095-g · Cited by 545
Association of p53 mutations with short survival in colorectal cancer
Hamelin, R., Laurent-Puig, P., Olschwang, S., Jego, N., Asselain, B., Remvikos, Y., Girodet, J., Salmon, R. J., & Thomas, G. (1994) · Gastroenterology · doi:10.1016/s0016-5085(94)94217-x · Cited by 345
Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up
Forbes, G. M., Glaser, M. E., Cullen, D., Collins, B. J., Warren, J. R., Christiansen, K., & Marshall, B. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91111-8 · Cited by 317
Iwahi, T., Satoh, H., Nakao, M., Iwasaki, T., Yamazaki, T., Kubo, K., Tamura, T., & Imada, A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.3.490 · Cited by 278
Antibacterial Treatment of Gastric Ulcers Associated with Helicobacter pylori
Sung, J. J. Y., Chung, S. C. S., Ling, T. K. W., Yung, M. Y., Leung, V. K. S., Ng, E. K. W., Li, M. K. K., Cheng, A. F. B., & Li, A. K. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501193320302 · Cited by 274
Cited by
Chopra, I., & Roberts, M. (2001) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.65.2.232-260.2001 · Cited by 4,517
Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications
Gerrits, M. M., van Vliet, A. H., Kuipers, E. J., & Kusters, J. G. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70627-2 · Cited by 329
Helicobacter in the developing world
Frenck, R. W., & Clemens, J. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(03)00112-6 · Cited by 310
16S rRNA Mutation-Mediated Tetracycline Resistance in Helicobacter pylori
Gerrits, M. M., de Zoete, M. R., Arents, N. L. A., Kuipers, E. J., & Kusters, J. G. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2996-3000.2002 · Cited by 137
Metadata
- Authors
- van Der Hulst, R. W. M., Keller, J. J., Rauws, E. A. J., & Tytgat, G. N. J.
- Venue
- Helicobacter
- Publisher
- Wiley
- Published
- 1996-03
- Volume
- 1
- Issue
- 1
- Pages
- 6-19
- ISSN
- 1083-4389 (ISSN-L)
- 1523-5378
- OpenAlex
- W2057863812
- Cited by
- 289
- References
- 45
- FWCI
- 42.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Helicobacter pylori Infection: A Review of the World Literature. https://app.cochat.ai/papers/10.1111/j.1523-5378.1996.tb00003.x
- The paper
- van Der Hulst, R. W. M., Keller, J. J., Rauws, E. A. J., & Tytgat, G. N. J. (1996). Treatment of Helicobacter pylori Infection: A Review of the World Literature. Helicobacter. https://doi.org/10.1111/j.1523-5378.1996.tb00003.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
